IO102-IO103
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for IO102-IO103, covering 2025-08-28 to 2026-03-13. Get the full timeline:
Most recent: Clinical Trial Update: IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer [Phase 1]